Potent Antitumor Efficacy of a Novel ALPPL2/ALPP-Targeting Antibody-Drug Conjugate in Preclinical Models
Antibody Therapeutics · 08.11.2026
DOI: 10.1093/abt/tbag055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibody Therapeutics, online erschienen am 08.11.2026. Verfasst von Lili Wang und 10 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The antitumor efficacy of antibody-drug conjugates (ADCs) is primarily determined by the tissue-specific distribution of target antigens. Placental alkaline phosphatase-like protein 2 (ALPPL2) and placental alkaline phosphatase (ALPP) are highly homologous and aberrantly overexpressed in multiple human malignancies, while minimally expressed in most normal adult tissues, rendering them ideal targets for tumor-targeted therapeutics. However, ALPPL2/ALPP-targeted therapeutics remain in their infancy, with no clinically approved agents, presenting a significant translational opportunity.
Methods
Antibodies were prepared via hybridoma technology. Their binding specificity, affinity, cross-species reactivity and internalization were characterized using flow cytometry and biolayer interferometry (BLI). Competitive epitope binning was applied to delineate the epitope diversity. Lead candidates were conjugated with monomethyl auristatin E (MMAE) to construct ALPPL2 ADCs, and their antitumor potency was systematically evaluated in vitro and in vivo across various tumor models.
Results
A panel of chimeric antibodies featuring high affinity, high specificity, and rapid internalization was generated and grouped into discrete epitope bins. The lead candidate AL71 shares substantial but non-identical epitope overlap with the benchmark SGN-ALPV and displays improved cross-reactivity against cynomolgus monkey ALPP. Critically, AL71-ADC surpasses SGN-ALPV, demonstrating enhanced in vitro cytotoxicity across multiple tumor cell models and potent in vivo antitumor activity in xenograft models.
Conclusions
AL71-ADC generated herein exhibits superior preclinical antitumor efficacy and cross-species reactivity relative to benchmark SGN-ALPV. Given the tumor-restricted expression of ALPPL2/ALPP alongside unmet clinical demands, AL71-ADC represents a promising therapeutic candidate for the treatment of ALPPL2/ALPP-positive malignancies.
Zitieren
APA
Wang, L., Zhang, X., Liu, G., He, X., Liu, J., Ji, S., Li, M., Xu, Y., Wang, X., Li, Y., & Yang, J. (2026). Potent Antitumor Efficacy of a Novel ALPPL2/ALPP-Targeting Antibody-Drug Conjugate in Preclinical Models. Antibody Therapeutics. https://doi.org/10.1093/abt/tbag055
Vancouver
Wang L, Zhang X, Liu G, He X, Liu J, Ji S, et al. Potent Antitumor Efficacy of a Novel ALPPL2/ALPP-Targeting Antibody-Drug Conjugate in Preclinical Models. Antibody Therapeutics. 2026. doi:10.1093/abt/tbag055
BibTeX
@article{Wang2026,
author = {Wang, Lili and Zhang, Xiaoping and Liu, Guohong and He, Xiaoli and Liu, Jianing and Ji, Shuya and Li, Mingyang and Xu, Yidan and Wang, Xiao and Li, Yuanhao and Yang, Jinliang},
title = {Potent Antitumor Efficacy of a Novel ALPPL2/ALPP-Targeting Antibody-Drug Conjugate in Preclinical Models},
journal = {Antibody Therapeutics},
year = {2026},
doi = {10.1093/abt/tbag055}
}
EUVIMED